Japanese encephalitis: Is there a need for a novel vaccine?

Expert Review of Vaccines

Volumn 8, Issue 8, 2009, Pages 969-972

  Wilder Smith, Annelies ^a   Freedman, David O ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIVAX; IXIARO; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG;

EDITORIAL; EPIDEMIC ENCEPHALITIS; HEALTH CARE ORGANIZATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; JAPANESE ENCEPHALITIS VIRUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PUBLIC HEALTH; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; YELLOW FEVER FLAVIVIRUS;

ASIA; ENCEPHALITIS, JAPANESE; HUMANS; JAPANESE ENCEPHALITIS VACCINES;

EID: 68049120131     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.69     Document Type: Editorial

References (38)

1. Burchard GD, Caumes E, Connor BA et al. Expert opinion on vaccination of travelers against Japanese encephalitis. J. Travel Med. 16(3), 204-216 (2009).
2. Monath TP. Japanese encephalitis vaccines: current vaccines and future prospects. Curr. Top. Microbiol. Immunol. 267, 105-138 (2002).
3. No authors listed. Japanese encephalitis vaccines. Wkly Epidemiol. Rev. 81(34/35), 331-340 (2006).
4. Fischer M, Casey C, Chen RT. Promise of new Japanese encephalitis vaccines. Lancet 370(9602), 1806-1808 (2007).
5. Endy TP, Nisalak A. Japanese encephalitis virus: ecology and epidemiology. Curr. Top. Microbiol. Immunol. 267, 11-48 (2002).
6. Basnyat B, Zimmerman MD, Shrestha Y, Scott RM, Endy TP. Persistent Japanese encephalitis in Kathmandu: the need for immunization. J. Travel Med. 8(5), 270-271 (2001).
7. Plesner AM. Allergic reactions to Japanese encephalitis vaccine. Immunol. Allergy Clin. North Am. 23(4), 665-697 (2003).
8. Plesner A, Ronne T, Wachmann H. Case-control study of allergic reactions to Japanese encephalitis vaccine. Vaccine 18(17), 1830-1836 (2000).
9. Plesner AM, Arlien-Soborg P, Herning M. Neurological complications to vaccination against Japanese encephalitis. Eur. J. Neurol. 5(5), 479-485 (1998).
10. Plesner AM, Ronne T. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine 15(11), 1239-1243 (1997).
11. Plesner AM, Arlien-Soborg P, Herning M. Neurological complications and Japanese encephalitis vaccination. Lancet 348(9021), 202-203 (1996).
12. Andersen MM, Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet 337(8748), 1044 (1991).
13. Hanna JN, Ritchie SA, Phillips DA et al. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med. J. Aust. 165(5), 256-260 (1996).
14. Konishi E, Suzuki T. Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations. Vaccine 21(1-2), 98-107 (2002).
15. Tsai TF. Flaviviruses (yellow fever, dengue, Japanese encephalitis, west Nile encephalitis, St Louis encephalitis, tick-borne encephalitis). In: Principles and Practice of Infectious Diseases (6th Edition). Mandell GL, Douglas R, Bennett JL (Eds). Elsevier, MO, USA, 1926-1950 (2005).
16. Hanna JN, Ritchie SA, Phillips DA et al. Japanese encephalitis in north Queensland, Australia, 1998. Med. J. Aust. 170(11), 533-536 (1999).
17. Arunachalam N, Samuel PP, Paramasivan R, Balasubramanian A, Tyagi BK. Japanese encephalitis in Gorakhpur Division, Uttar Pradesh. Indian J. Med. Res. 128(6), 775-777 (2008).
18. Bista MB, Shrestha JM. Epidemiological situation of Japanese encephalitis in Nepal. J. Nepal Med. Assoc. 44(158), 51-56 (2005).
19. Gingrich JB, Nisalak A, Latendresse JR et al. A longitudinal study of Japanese encephalitis in suburban Bangkok, Thailand. Southeast Asian J. Trop. Med. Public Health 18(4), 558-566 (1987).
20. Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. Emerg. Infect. Dis. 15(1), 1-7 (2009).
21. Wittesjo B, Eitrem R, Niklasson B, Vene S, Mangiafico JA. Japanese encephalitis after a 10-day holiday in Bali. Lancet 345(8953), 856-857 (1995).
22. Buhl MR, Black FT, Andersen PL, Laursen A. Fatal Japanese encephalitis in a Danish tourist visiting Bali for 12 days. Scand. J. Infect. Dis. 28(2), 189 (1996).
23. Buhl MR, Lindquist L. Japanese encephalitis in travelers: review of cases and seasonal risk. J. Travel Med. 16(3), 217-219 (2009).
24. Zanin MP, Webster DE, Martin JL, Wesselingh SL. Japanese encephalitis vaccines: moving away from the mouse brain. Expert Rev. Vaccines 2(3), 407-416 (2003).
25. Halstead SBJ. Japanese encephalitis vaccines. In: Vaccines (5th Edition). Plotkin SO, Orenstein W, Offit P (Eds). Elsevier, PA, USA, 311-352 (2008).
26. Hennessy S, Liu Z, Tsai TF et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-12): a case-control study. Lancet 347(9015), 1583-1586 (1996).
27. Monath TP, Levenbook I, Soike K et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. Virol. 74(4), 1742-1751 (2000).
28. Tandan JB, Ohrr H, Sohn YM et al. Single dose of SA 14-14-12 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com. Vaccine 25(27), 5041-5045 (2007).
29. Jones T. ChimeriVax-JE. Acambis. Curr. Opin. Investig. Drugs 4(8), 1019-1022 (2003).
30. Jones T. A chimeric live attenuated vaccine against Japanese encephalitis. Expert Rev. Vaccines 3(3), 243-248 (2004).
31. Bhatt TR, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14 14 12), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am. J. Trop. Med. Hyg. 62(4), 480-484 (2000).
32. Monath TP, McCarthy K, Bedford P et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20(7-8), 1004-1018 (2002).
33. Lobigs M, Larena M, Alsharifi M, Lee E, Pavy M. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J. Virol. 83(6), 2436-2445 (2009).
34. Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet 363(9426), 2073-2075 (2004).
35. Barnett ED, Wilder-Smith A, Wilson ME. Yellow fever vaccines and international travelers. Expert Rev. Vaccines 7(5), 579-587 (2008).
36. Lindsey NP, Schroeder BA, Miller ER et al. Adverse event reports following yellow fever vaccination. Vaccine 26(48), 6077-6082 (2008).
37. Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cellderived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomised controlled trial. Lancet 370(9602), 1847-1853 (2007).
38. Tauber E, Kollaritsch H, von Sonnenburg F et al. Randomized, double-blind, placebo-controlled Phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J. Infect. Dis. 198(4), 493-499 (2008).